

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ocumention Therapeutics
歐康維視生物

(Incorporated in the Cayman Islands with limited liability)
 (Stock Code: 1477)

**CLARIFICATION ANNOUNCEMENT IN RELATION TO
 PLACING OF EXISTING SHARES BY CONTROLLING SHAREHOLDERS**

Reference is made to the announcement (the “**Announcement**”) of Ocumention Therapeutics (the “**Company**”) dated June 10, 2021 in relation to the placing of existing Shares by the Controlling Shareholders of the Company. Unless otherwise specified, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Company would like to clarify that there was an inadvertent clerical error on page 2 of the Announcement in relation to the shareholding structure of the Company. The existing shareholding structure of the Company as of the date of the Announcement and the effect on the shareholding structure of the Company upon completion of the Placing should be as follows.

	Shareholding as of the date of the Announcement		Shareholding immediately upon completion of the Placing (assuming fully placed) ⁽¹⁾	
	Number of Shares held	Approximate % of Shares in issue	Number of Shares held	Approximate % of Shares in issue
Controlling Shareholders				
6 Dimensions Capital, L.P. ⁽²⁾	123,975,000	19.68%	119,890,000	19.03%
6 Dimensions Affiliates Fund, L.P. ⁽²⁾	6,525,000	1.04%	6,310,000	1.00%
<u>Suzhou 6Dimensions Venture Capital Partnership L.P.</u> ⁽³⁾	39,150,000	6.21%	37,860,000	6.01%
<u>Suzhou Frontline BioVentures Venture Capital Fund II L.P.</u> ⁽³⁾	91,350,000	14.50%	88,340,000	14.02%
Placee(s)	–	–	8,600,000	1.36%
Other shareholders of the Company	369,074,305	58.58%	369,074,305	58.58%
Total	<u>630,074,305</u>	<u>100%</u>	<u>630,074,305</u>	<u>100.00%</u>

Notes:

1. Assuming no other issue of Shares and no repurchase of existing Shares before completion of the Placing.
2. For the purpose of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong) (the “SFO”), 6 Dimensions Capital GP, LLC, as the general partner of each of 6 Dimensions Capital, L.P. and 6 Dimensions Affiliates Fund, L.P., is deemed to have an interest in the Shares held by each of 6 Dimensions Capital, L.P. and 6 Dimensions Affiliates Fund, L.P.
3. For the purpose of the SFO, (i) Suzhou Fuyan Venture Capital Management Partnership (Limited Partnership) (蘇州富沿創業投資管理合夥企業(有限合夥)) is deemed to have an interest in the Shares held by Suzhou Frontline BioVentures Venture Capital Fund II L.P. as its general partner; (ii) Suzhou Tongyu Investment Management Partnership (Limited Partnership) (蘇州通毓投資管理合夥企業(有限合夥)) is deemed to have an interest in the Shares held by Suzhou 6Dimensions Venture Capital Partnership L.P. as its general partner; and (iii) Suzhou Yunchang Investment Consulting Co., Ltd. (蘇州蘊長投資諮詢有限公司) (as the general partner of Suzhou Fuyan Venture Capital Management Partnership (Limited Partnership) and Suzhou Tongyu Investment Management Partnership (Limited Partnership)) and Ziqing CHEN (陳梓卿) (as the beneficial owner of Suzhou Yunchang Investment Consulting Co., Ltd.) are deemed to have an interest in the Shares held by each of Suzhou Frontline BioVentures Venture Capital Fund II L.P. and Suzhou 6Dimensions Venture Capital Partnership L.P.

Save for the above clarification, all other information in the Announcement remains unchanged.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Executive Director

Hong Kong, June 15, 2021

As of the date of this announcement, the Board comprises Dr. Lian Yong CHEN, Mr. Ye LIU, Dr. Zhaopeng HU and Dr. Wei LI as executive Directors, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive Directors, and Mr. Ting Yuk Anthony WU, Mr. Lianming HE, and Mr. Yiran HUANG as independent non-executive Directors.